With this in mind, we took the decision to conduct a combined systematic review, meta-analysis, and bioinformatics validation of skeletal (and non-skeletal) studies to interrogate the hypothesis that genetic and pharmacological modulation of the classical CB1, CB2 receptors or both are associated with significant reduction in cancer-induced pain, including bone pain, in animal models and humans. The gene discussed is CNR1; the disease is cancer.